Author and year | n | Tracer | Clinical state | Study | Purpose and endpoint | Statistical method | Conclusion |
---|---|---|---|---|---|---|---|
Even-Sapir et al. (48), 2006 | 44 | 18F-fluoride | Initial staging (25) | Prospective | Purpose: disease detection (bone) | Sensitivity, specificity | PET: |
Metastatic (19) | Endpoints: | Sensitivity, 100% | |||||
Lesions assessed with CIM | Specificity, 62% | ||||||
Histopathology | PET/CT: | ||||||
Follow-up of CIM | Sensitivity, 100% | ||||||
Clinical follow-up | Specificity, 100% | ||||||
Beheshti et al., (57) 2008 | 38 | 18F-FCH | Initial staging (17) | Prospective | Purpose: disease detection (bone) | Lesion-based sensitivity, specificity | 18F-FCH: |
18F-fluoride | Metastatic castration-sensitive (21) | Endpoints: | Sensitivity, 74% | ||||
Lesions assessed with CT (from PET/CT) | Specificity, 99% | ||||||
Histopathology | 18F-fluoride: | ||||||
Follow-up of PET/CT | Sensitivity, 81% | ||||||
Specificity, 93% |
CIM = conventional imaging modality.